FDA Approvals, News & UpdatesOvarian Cancer

Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
June 2020 Vol 6 No 3

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy. Zejula was previously approved for several types of ovarian cancer, including patients with HRD-positive disease, defined by the presence of the BRCA gene mutation or genomic instability.

Since late 2018, women with ovarian cancer and a BRCA mutation whose cancer responded to initial treatment with chemotherapy were eligible to receive treatment with a PARP inhibitor, including Zejula or Lynparza (olaparib).

This approval was based on the results of a clinical trial of 733 patients with ovarian cancer who had a response to first-line platinum-based chemotherapy. Patients received first-line maintenance treatment with Zejula or with placebo.

The results showed significantly longer time without cancer progression in patients who received Zejula compared with patients who received placebo, regardless of HRD status. The average time without cancer progression in patients with HRD-positive status was 21.9 months with Zejula versus 10.4 months with placebo. The average time without cancer progression in all the patients was 13.8 months with Zejula versus 8.2 months with placebo.

The most common side effects with Zejula in the PRIMA study were thrombocytopenia (reduced platelets), anemia, nausea, fatigue, neutropenia, constipation, muscle pain, headache, insomnia, vomiting, dyspnea, decreased appetite, dizziness, cough, hypertension, and kidney injury.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Last modified: July 7, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.